Literature DB >> 20626297

Predominant interferon-γ-mediated expression of CXCL9, CXCL10, and CCL5 proteins in the brain during chronic infection with Toxoplasma gondii in BALB/c mice resistant to development of toxoplasmic encephalitis.

Xiangshu Wen1, Tomoya Kudo, Laura Payne, Xisheng Wang, Laurel Rodgers, Yasuhiro Suzuki.   

Abstract

We examined the role of interferon-γ (IFN-γ) in expression of chemokine mRNA and proteins in the brain during chronic infection with Toxoplasma gondii using BALB/c and BALB/c-background IFN-γ knockout (IFN-γ(-/-)) mice. BALB/c mice are genetically resistant to development of toxoplasmic encephalitis and establish a latent, chronic infection in the brain through IFN-γ-mediated immune responses. Amounts of mRNA for CXCL9/MIG, CXCL10/IP-10, CXCL11/I-TAC, CCL2/MCP-1, CCL3/MIP-1α, and CCL5/RANTES significantly increased in the brains of wild-type mice after infection. CXCL9/MIG, CXCL10/IP-10, and CCL5/RANTES mRNA were most abundant among these chemokines. An increase in amounts of mRNA for CXCL10/IP-10, CCL2/MCP-1, CCL3/MIP-1α, and CCL5/RANTES was also observed in the brains of IFN-γ(-/-) mice after infection, although CXCL10/I-10 and CCL5/RANTES mRNA levels in infected IFN-γ(-/-) mice were significantly lower than those of infected wild-type animals. Amounts of mRNA for CXCL9/MIG and CXCL11/I-TAC remained at the basal levels in infected IFN-γ(-/-) mice. When amounts of the chemokine proteins were examined in the brain homogenates of uninfected and infected mice of both strains, large amounts of CXCL9/MIG, CXCL10/IP-10, and CCL5/RANTES were detected only in infected wild-type animals. These results indicate that CXCL9/MIG, CXCL10/IP-10, and CCL5/RANTES are the chemokines predominantly induced in the brains of genetically resistant BALB/c mice during chronic infection with T. gondii, and their expression is dependent on IFN-γ.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626297      PMCID: PMC2963637          DOI: 10.1089/jir.2009.0119

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  34 in total

1.  IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection.

Authors:  I A Khan; J A MacLean; F S Lee; L Casciotti; E DeHaan; J D Schwartzman; A D Luster
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

2.  Expression of Mig (monokine induced by interferon-gamma) is important in T lymphocyte recruitment and host defense following viral infection of the central nervous system.

Authors:  M T Liu; D Armstrong; T A Hamilton; T E Lane
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

3.  Requirement of non-T cells that produce gamma interferon for prevention of reactivation of Toxoplasma gondii infection in the brain.

Authors:  H Kang; Y Suzuki
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Gamma interferon-induced inhibition of Toxoplasma gondii in astrocytes is mediated by IGTP.

Authors:  S K Halonen; G A Taylor; L M Weiss
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  [Genotyping of Toxoplasma gondii strains from immunocompromised patients].

Authors:  S Honoré; A Couvelard; Y J Garin; C Bedel; D Hénin; M L Dardé; F Derouin
Journal:  Pathol Biol (Paris)       Date:  2000-07

6.  Chemokines are differentially expressed by astrocytes, microglia and inflammatory leukocytes in Toxoplasma encephalitis and critically regulated by interferon-gamma.

Authors:  Andreas Strack; Valérie C Asensio; Iain L Campbell; Dirk Schlüter; Martina Deckert
Journal:  Acta Neuropathol       Date:  2002-01-31       Impact factor: 17.088

Review 7.  Lymphocyte traffic control by chemokines.

Authors:  B Moser; P Loetscher
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

8.  IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE).

Authors:  N H R Hamilton; J L Banyer; A J Hapel; S Mahalingam; A J Ramsay; I A Ramshaw; S A Thomson
Journal:  Scand J Immunol       Date:  2002-02       Impact factor: 3.487

9.  Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis.

Authors:  Andrea Salmaggi; Maurizio Gelati; Anna Dufour; Elena Corsini; Stefano Pagano; Rossana Baccalini; Elisabetta Ferrero; Silvia Scabini; Valerio Silei; Emilio Ciusani; Marco De Rossi
Journal:  J Interferon Cytokine Res       Date:  2002-06       Impact factor: 2.607

10.  Neutralization of chemokines RANTES and MIG increases virus antigen expression and spinal cord pathology during Theiler's virus infection.

Authors:  Daren R Ure; Thomas E Lane; Michael T Liu; Moses Rodriguez
Journal:  Int Immunol       Date:  2005-04-11       Impact factor: 4.823

View more
  30 in total

Review 1.  Interferon-gamma- and perforin-mediated immune responses for resistance against Toxoplasma gondii in the brain.

Authors:  Yasuhiro Suzuki; Qila Sa; Marie Gehman; Eri Ochiai
Journal:  Expert Rev Mol Med       Date:  2011-10-04       Impact factor: 5.600

Review 2.  The molecular biology and immune control of chronic Toxoplasma gondii infection.

Authors:  Xiao-Yu Zhao; Sarah E Ewald
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

3.  Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-γ signal transduction pathways.

Authors:  Dan Li; Jin Wei; Fan Yang; Hua-Nan Liu; Zi-Xiang Zhu; Wei-Jun Cao; Shu Li; Xiang-Tao Liu; Hai-Xue Zheng; Hong-Bing Shu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 4.  The immune system utilizes two distinct effector mechanisms of T cells depending on two different life cycle stages of a single pathogen, Toxoplasma gondii, to control its cerebral infection.

Authors:  Yasuhiro Suzuki
Journal:  Parasitol Int       Date:  2019-11-25       Impact factor: 2.230

5.  Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

Authors:  Chien-Chun Steven Pai; John T Huang; Xiaoqing Lu; Donald M Simons; Chanhyuk Park; Anthony Chang; Whitney Tamaki; Eric Liu; Kole T Roybal; Jane Seagal; Mingyi Chen; Katsunobu Hagihara; Xiao X Wei; Michel DuPage; Serena S Kwek; David Y Oh; Adil Daud; Katy K Tsai; Clint Wu; Li Zhang; Marcella Fasso; Ravi Sachidanandam; Anitha Jayaprakash; Ingrid Lin; Amy-Jo Casbon; Gillian A Kinsbury; Lawrence Fong
Journal:  Immunity       Date:  2019-02-05       Impact factor: 31.745

6.  Persistent Toxoplasma Infection of the Brain Induced Neurodegeneration Associated with Activation of Complement and Microglia.

Authors:  Ye Li; Emily G Severance; Raphael P Viscidi; Robert H Yolken; Jianchun Xiao
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

Review 7.  Viral infection, inflammation and schizophrenia.

Authors:  Rachel E Kneeland; S Hossein Fatemi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-10       Impact factor: 5.067

8.  CXCL9 is important for recruiting immune T cells into the brain and inducing an accumulation of the T cells to the areas of tachyzoite proliferation to prevent reactivation of chronic cerebral infection with Toxoplasma gondii.

Authors:  Eri Ochiai; Qila Sa; Morgan Brogli; Tomoya Kudo; Xisheng Wang; Jitender P Dubey; Yasuhiro Suzuki
Journal:  Am J Pathol       Date:  2014-11-26       Impact factor: 4.307

Review 9.  Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis.

Authors:  Hany M Elsheikha; Christina M Marra; Xing-Quan Zhu
Journal:  Clin Microbiol Rev       Date:  2020-11-25       Impact factor: 26.132

10.  Quiescent innate response to infective filariae by human Langerhans cells suggests a strategy of immune evasion.

Authors:  Alexis Boyd; Sasisekhar Bennuru; Yuanyuan Wang; Vivornpun Sanprasert; Melissa Law; Damien Chaussabel; Thomas B Nutman; Roshanak Tolouei Semnani
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.